- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05662670
A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of WJ13405 Monotherapy in Patients With Advanced or Mentastatic Non-Small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Yongdong Zhang
- Phone Number: +86 18042483763
- Email: yongdong_zhang@junshipharma.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200433
- Recruiting
- Shanghai Pulmonary Hospital
-
Contact:
- Banyu Zhang
- Phone Number: 86 021-65115006
- Email: Shfkgcp@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥ 18 years old, male or female;
- Histologically or cytologically confirmed locally advanced or recurrent/metastatic advanced NSCLC that is inoperable, is subject to progression or intolerability after the standard of care, or is unable to be treated or has not been treated by the standard of care;
- Dose escalation: patients with EGFR sensitive mutation who have experienced disease progression after third-generation EGFR-TKI therapy;
- Dose expansion and efficacy expansion: patients with proven EGFR C797X mutation;
- Patients who agree to provide tumor tissues and blood samples for EGFR mutation analysis (certain patients who are unable to provide qualified tumor tissues may be enrolled once approved by investigators and the Sponsor);
- At least one measurable lesion as per RECIST v1.1;
- ECOG PS score of 0-1;
- Expected survival of more than 12 weeks;
Sufficient vital organ functions at screening (requiring no blood transfusion, use of hematopoietic stimulating factor, or use of human albumin preparation within 14 days before screening):
- ANC ≥ 1.5 × 109/L;
- Platelet ≥ 100 × 109/L;
- Hemoglobin > 90 g/L;
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.0 × upper limit of normal (ULN) (in the presence of liver metastasis, ≤ 5 × ULN);
- Total bilirubin (TBIL) ≤ 1.5 × ULN;
- Coagulation function (INR) ≤ 1.5 × ULN;
- Blood creatinine ≤ 1.5 × ULN or creatinine clearance (Ccr, calculated by the Cockcroft-Gault formula) ≥ 45 mL/min;
- Serum lipase and amylase ≤ 1.5 × ULN;
- Females with childbearing potential and a negative serum pregnancy test within 7 days before enrollment who agree to use effective contraception during the IMP treatment and 6 months after the last dose. This protocol defines "females with childbearing potential" as sexually mature women who: 1) have not undergone a hysterectomy or bilateral ovariectomy; 2) have not had spontaneous menopause for 24 consecutive months (i.e., no menstrual bleeding at any time within the last 24 consecutive months; amenorrhea after cancer treatment does not indicate infertility). Male patients whose sexual partners are females with childbearing potential must agree to use effective contraception during the study treatment and 6 months after the last dose;
- Patients who voluntarily participate in this study and have signed the informed consent form after an all-inclusive informed consent process.
Exclusion Criteria:
- Patients who have received systemic anti-tumor therapy within 4 weeks before the first dose, including chemotherapy, targeted therapy, anti-vascular drug therapy, biologic therapy, immunotherapy, radiotherapy, or other IMP therapy; moreover, patients who have received EGFR-TKI targeted therapy may be enrolled if 5 half-lives have passed after discontinuation;
- Patients who are receiving strong CYP3A inhibitors or inducers; or those who have yet to reach 5 half-lives after discontinuation of a strong inhibitor, or 5 half-lives or 14 days (whichever is longer) after discontinuation of a strong inducer at the time of the first WJ13404 dosing;
- Patients who have experienced adverse events caused by previous anti-tumor therapy that have yet to improve to CTCAE v5.0 grade ≤ 1 at screening (except for neurotoxicity and alopecia, which cannot be recovered as assessed by investigators);
- Patients who are plagued by other malignancies (except for non-melanoma basal or squamous cell carcinoma of the skin, carcinoma in situ of the breast/cervix, superficial bladder cancer, thyroid cancer, and other carcinomas in situ, treated with curative intent and without evidence of recurrent disease) concurrently or within 5 years before treatment initiation;
- History of diseases causing chronic diarrhea, including but not limited to Crohn's disease and irritable bowel syndrome;
- Active gastrointestinal disease or other conditions that may significantly compromise drug absorption, metabolism, or excretion;
- Patients known to have undergone organ transplantation or stem cell transplantation; patients who have undergone major surgery or serious trauma within 4 weeks before the first dose (excluding needle biopsy for sample collection);
- Patients who are suffering from carcinomatous meningitis and spinal cord compression;
- Patients who meet one of the following cardiac criteria: Unexplained or cardiovascular-caused presyncope or syncope, ventricular tachycardia, ventricular fibrillation, or cardiac arrest, with average corrected QT interval (based on 3 ECGs taken at rest, QTc, using the Fridericia's correction formula) > 450 ms in males or > 470 ms in females. Various clinically significant cardiac rhythm, conduction, or resting ECG morphological abnormalities, such as complete left bundle branch block, third-degree conduction block, second-degree conduction block, PR interval > 250 ms, and echocardiography-suggested left ventricular ejection fraction (LVEF) < 50%. Various factors that may increase the risks of QTc prolongation or arrhythmic events, such as heart failure, hypokalemia, congenital long QT syndrome, history of immediate family members with long QT syndrome or sudden death of unknown cause before age 40, and current receipt of any drug known to prolong the QT interval;
- Unstable systemic diseases, such as active infection requiring systemic drug therapy, poorly controlled hypertension, unstable angina, congestive heart failure, serious hepatic, renal, or metabolic conditions including cirrhosis, renal failure, and uremia;
- Patients who experience dyspnea or require continuous oxygen therapy, or who are suffering from CTCAE v5.0 grade ≥ 2 active pneumonitis or interstitial lung disease (except mild radiation pneumonitis);
- Central nervous system metastasis with symptoms. Patients who have received treatment for brain metastases may be considered for enrollment, provided that no disease progression confirmed by radiologic imaging evaluation occurs within 4 weeks before the first dose of the IMP, no evidence shows new or enlarging brain metastases, and radiation, surgery, or steroid therapy has been discontinued for at least 4 weeks before the first dose of the IMP;
- HBV-RNA > upper limit of the reference value when positive for hepatitis B surface antigen or hepatitis B core antibody;
- HCV-RNA > upper limit of the reference value when positive for hepatitis C antibody;
- Positive for human immunodeficiency virus (HIV);
- Patients with a confirmed history of mental disorders who are receiving drugs for treatment;
- History of substance or drug abuse;
- Patients who have received traditional Chinese medicine for anti-tumor therapy within 1 week before the first dose of the study treatment;
- Previous serious eye disorders that have not recovered to grade ≤ 1;
- Skin toxicity at > grade 2 within 4 weeks before the first dose;
- Pregnancy and lactation;
- Other factors, as evaluated by investigators, that have potential effects on study results and may interfere with the patient's participation, including previous or existing physical conditions (such as eye disorders, including corneal ulcers and conjunctivitis), treatment or laboratory test abnormalities, patient unwillingness to abide by the study procedures, restrictions, and requirements, and the presence of psychological or social conditions that may interfere with their participation or affect the study result evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental:WJ13404 tablets
Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily. (It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor). Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D. Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied. |
Dose escalation: 6 dose levels The dose escalation study is proposed to include 6 dose levels: 30, 90, 180, 270, 360, and 480 mg once daily. (It can be adjusted based on clinical PK data and safety results after discussion between PI and the sponsor). Dose-expansion: After the initial data evaluation, the Sponsor and the SMC will select 2-3 dose levels to evaluate drug safety and PK further, explore its preliminary efficacy, and determine RP2D. Efficacy expansion: The RP2D determined in dose escalation and dose expansion will be applied. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events(AE) and serious adverse events(SAE)
Time Frame: up to 3 years
|
To evaluate incidence,severity and outcome of adverse events(AE),and serious adverse events(SAE)
|
up to 3 years
|
ORR
Time Frame: up to 3 years
|
Proportion of patients who have the best response of confirmed or partial response as per RECIST v1.1.ORR, along with its 95% CI, will be calculated
|
up to 3 years
|
DLT
Time Frame: up to 2 years (only for dose escalation and dose expansion)
|
DLT is defined as any of the following toxicities that occur during the DLT observation and are deemed by investigators possibly, probably, or definitely related to WJ13404 as per NCI-CTCAE v5.0
|
up to 2 years (only for dose escalation and dose expansion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension ,maximum plasmaconcentration
|
up to 3 years
|
Tmax
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,time to Cmax
|
up to 3 years
|
AUC 0-t
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,area under the concentration versus time curve from time 0 to the last measurable concentration.
|
up to 3 years
|
t1/2
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, elimination half-life.
|
up to 3 years
|
CL/F
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, clearance.
|
up to 3 years
|
Vd/F
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extensionapparent volume of distribution
|
up to 3 years
|
λz
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, elimination rate constant.
|
up to 3 years
|
Css-min
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,minimum concentration at steady state.
|
up to 3 years
|
Css-max
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,maximum concentration at steady state.
|
up to 3 years
|
Css-ave
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, average concentration at steady state.
|
up to 3 years
|
AUCtau-ss
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,area under the concentration versus time curve for a dosing interval at steady state.
|
up to 3 years
|
Vss
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,volume of distribution at steady state.
|
up to 3 years
|
AR
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,accumulation ratio.
|
up to 3 years
|
DF
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,degree of fluctuation.
|
up to 3 years
|
ORR
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, objective response rate.
|
up to 3 years
|
DOR
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, duration of response.
|
up to 3 years
|
DCR
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, disease control rate.
|
up to 3 years
|
PFS
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension, progression-free survival.
|
up to 3 years
|
OS
Time Frame: up to 3 years
|
It's suitable for dose escaltion and does extension,overall survival.
|
up to 3 years
|
adverse events(AE) and serious adverse events(SAE)
Time Frame: up to 1 years(only for efficacy expansion stage)
|
To evaluate incidence,severity and outcome of adverse events(AE),and serious adverse events(SAE)
|
up to 1 years(only for efficacy expansion stage)
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JS113-001-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced or Metastatic NSCLC
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR Mutated NSCLC.Taiwan
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic NSCLCChina
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterActive, not recruitingLocally Advanced or Metastatic NSCLCKorea, Republic of
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of, China, Japan
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR T790M+ NSCLCCanada, Korea, Republic of, Taiwan
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
LetolabNot yet recruitingLocally Advanced or Metastatic CRC
Clinical Trials on WJ13404 tablets
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam
-
Cara Therapeutics, Inc.RecruitingPruritus | Notalgia ParestheticaUnited States, Poland, Spain, Canada, Germany
-
Jiangsu vcare pharmaceutical technology co., LTDCompletedInflammatory Bowel DiseasesChina
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Not yet recruitingHematologic MalignancyChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingModerate to Severe Atopic DermatitisChina
-
Shenzhen NewDEL Biotech, Co., LtdShenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.Enrolling by invitation
-
Akros Pharma Inc.CompletedSkin Diseases | Psoriasis | Plaque PsoriasisUnited States, Canada, Poland